Oxford BioTherapeutics to develop bispecifics using WuXi Biologics’ platform

Oxford BioTherapeutics Ltd. (Abingdon, U.K.) hopes to treat patients who do not benefit from existing immunotherapies

Read the full 163 word article

User Sign In